Rocket Pharmaceuticals Inc
BiotechRocket Pharmaceuticals Inc is a biotechnology company with 1 FDA-approved products.
Rocket Pharmaceuticals Inc's Key Drugs
Rocket Pharmaceuticals Inc's core commercial portfolio centers on kresladi — its most strategically important drugs approved in the last 15 years.
Rocket Pharmaceuticals Inc News
All Rocket Pharmaceuticals Inc news →- Nov 12, 2026 EarningsRocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress ↗
- Oct 7, 2026 TrialsRocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar ↗
- Oct 6, 2026 DealsRocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital ↗
- Sep 15, 2026 RegulatoryRocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease ↗
Rocket Pharmaceuticals Inc's Recent FDA Approvals
Rocket Pharmaceuticals Inc secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
Rocket Pharmaceuticals Inc's Therapeutic Areas
Disease areas where Rocket Pharmaceuticals Inc has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Rocket Pharmaceuticals Inc Pipeline Snapshot
Active clinical trials for Rocket Pharmaceuticals Inc across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • kresladi leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/0 completed
- • Speed: 49 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2026-03-26
- Latest
- 2026-03-26
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges